The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies

Journal of Neuroimmunology

Volumn 166, Issue 1-2, 2005, Pages 180-188

  Pachner, Andrew R ^a   Dail, Donna ^a   Pak, Elena ^a   Narayan, Kavitha ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Bioactivity; Gene expression; Interferon beta; Multiple sclerosis; Neutralizing antibody

Indexed keywords

BETA INTERFERON; CYTOKINE; INTERFERON ANTIBODY; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; ANTIBODY; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEINS;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; ASSAY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOLOGICAL MONITORING; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BINDING; BLOOD; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; LABORATORY DIAGNOSIS; METABOLISM; TIME;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE REACTIONS; FEMALE; GENE EXPRESSION; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; RNA, MESSENGER; TIME FACTORS;

EID: 23144458935     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2005.06.003     Document Type: Article

References (39)

1. R.M. Arduini, K.L. Strauch, L.A. Runkel, M.M. Carlson, X. Hronowski, S.F. Foley, C.N. Young, W. Cheng, P.S. Hochman, and D.P. Baker Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains Protein Sci. 8 1999 1867 1877
2. J. Bekisz, H. Schmeisser, J. Hernandez, N.D. Goldman, and K.C. Zoon Human interferons alpha, beta and omega Growth Factors 22 2004 243 251
3. K. Bendtzen Anti-IFN BAb and NAb antibodies; a minireview Neurology 61 2003 S6 S10
4. A. Bertolotto, F. Gilli, A. Sala, L. Audano, A. Castello, U. Magliola, F. Melis, and M.T. Giordana Evaluation of bioavailability of three types of IFNb in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification J. Immunol. Methods 256 2001 141 152
5. A. Bertolotto, F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R.L. Lindberg, R. Bottero, A. Di Sapio, and M.T. Giordana Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients Neurology 60 2003 634 639
6. A. Bertolotto, A. Sala, S. Malucchi, F. Marnetto, M. Caldano, A. Di Sapio, M. Capobianco, and F. Gilli Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies J. Neurol. Neurosurg. Psychiatry 75 2004 1294 1299
7. M. Brickelmaier, P.S. Hochman, R. Baciu, B. Chao, J.H. Cuervo, and A. Whitty ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β J. Immunol. Methods 227 1999 121 135
8. F. Casoni, E. Merelli, R. Bedin, P. Sola, A. Bertolotto, and P. Faglioni Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis? Acta Neurol. Scand. 109 2004 61 65
9. S.D. Cook, J.R. Quinless, A. Jotkowitz, P. Beaton, and T.N.A.S. Group Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients Neurology 57 2001 1080 1084
10. E.C. Cutrone, and J.A. Langer Identification of critical residues in Bovine IFNAR-1 responsible for interferon binding J. Biol. Chem. 276 2000 17140 17148
11. F. Deisenhammer, M. Reindl, J. Harvey, T. Gasse, E. Dilitz, and T. Berger Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies Neurology 52 1999 1239 1243
12. F. Deisenhammer, I. Mayringer, J. Harvey, E. Dilitz, T. Gasse, D. Stadlbauer, M. Reindl, and T. Berger A comparative study of the relative bioavailability of different interferon beta preparations Neurology 54 2000 2055 2060
13. F. Deisenhammer, C. Gneiss, F. Reichartseder, M. Reindl, and T. Berger Comparative study of neutralizing antibody titers against the three different interferon-beta preparations Presented at the American Academy of Neurology Meeting, 2005 2005
14. F. Gilli, A. Sala, C. Bancone, P. Salacone, M. Gallo, E. Gaia, and A. Bertolotto Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients J. Immunol. Methods 262 2002 187 190
15. F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R.L. Lindberg, and D. Leppert Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs Brain 127 2004 259 268
16. F. Gilli, F. Marnetto, M. Caldano, A. Sala, S. Malucchi, A. Di Sapio, M. Capobianco, and A. Bertolotto Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis J. Neuroimmunol. 158 2005 195 203
17. G. Giovannoni, F.E. Munschauer III, and F. Deisenhammer Neutralising antibodies to interferon beta during the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry 73 2002 465 469
18. J. Hong, Y.C. Zang, G. Hutton, V.M. Rivera, and J.Z. Zhang Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis J. Neuroimmunol. 152 2004 126 139
19. F. Koike, J. Satoh, S. Miyake, T. Yamamoto, M. Kawai, S. Kikuchi, K. Nomura, K. Yokoyama, K. Ota, T. Kanda, T. Fukazawa, and T. Yamamura Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis J. Neuroimmunol. 139 2003 109 118
20. S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis Neurology 62 2004 2031 2037
21. V. Ozenci, M. Kouwenhoven, Y.M. Huang, B. Xiao, P. Kivisakk, S. Fredrikson, and H. Link Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment Scand. J. Immunol. 49 1999 554 561
22. A. Pachner Anti-IFNβ antibodies in IFNβ-treated MS patients: summary Neurology 61 Suppl. 5 2003 1 5
23. A.R. Pachner An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients Neurology 61 2003 1444 1446
24. A. Pachner, K. Narayan, N. Price, M. Hurd, and D. Dail MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity Mol. Diagn. 7 2003 17 25
25. A.R. Pachner, A. Bertolotto, and F. Deisenhammer Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB) Neurology 61 2003 S24 S26
26. H. Panitch, D.S. Goodin, G. Francis, P. Chang, P.K. Coyle, P. O'Connor, E. Monaghan, D. Li, and B. Weinshenker Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial Neurology 59 2002 1496 1506
27. PRISMS-Study-Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis Lancet 352 1998 1498 1504
28. PRISMS-Study-Group PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS Neurology 56 2001 1628 1636
29. E. Pungor, J.G. Files, J.D. Gabe, L.T. Do, W.P. Foley, J.L. Gray, J.W. Nelson, E. Nestaas, J.L. Taylor, and S.E. Grossberg A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b J. Interferon Cytokine Res. 18 1998 1025 1030
30. G. Rice, B. Incorvaia, L. Munari, G. Ebers, C. Pohlman, R. D'Amico, and G. Filippini Interferon in Relapsing-Remitting Multiple Sclerosis (Cochrane Review) 2001 The Cochrane Library Oxford
31. N.D. Richert, M.C. Zierak, C.N. Bash, B.K. Lewis, H.F. McFarland, and J.A. Frank MRI and clinical activity in MS patients after terminating treatment with interferonβ Mult. Scler. 6 2000 86 90
32. R.A. Rudick, N.A. Simonian, J.A. Alam, M. Campion, J.O. Scaramucci, W. Jones, M.E. Coats, D.E. Goodkin, B. Weinstock-Guttman, R.M. Herndon, M.K. Mass, J.R. Richert, A.M. Salazar, F.E. Munschauer III, D.L. Cookfair, J.H. Simon, and J. LD. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology 50 1998 1206 1208
33. P.S. Sorensen, C. Ross, K.M. Clemmesen, K. Bendtzen, J.L. Frederiksen, K. Jensen, O. Kristensen, T. Petersen, S. Rasmussen, M. Ravnborg, E. Stenager, and N. Koch-Henriksen Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis Lancet 362 2003 1184 1191
34. P.S. Sorensen, N. Koch-Henriksen, C. Ross, K. Bendtzen, and D.M.S. Group Dynamics of neutralizing anti-interferon antibodies in multiple sclerosis during interferon-beta therapy Presented at the American Academy of Neurology Meeting, 2004 2004
35. S. Sturzebacher, R. Maibauer, A. Heuner, K. Beckmann, and B. Aufdembrinke Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers J. Interferon Cytokine Res. 19 1999 1257 1264
36. The-IFNB-Multiple-Sclerosis-Study-Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis Neurology 43 1993 661 665
37. A.-M. Vallittu, M. Halminen, J. Peltoniemi, J. Ilonen, I. Julkunen, A. Salmi, J.-P. Eralinna, and F.B.-I.S. Group Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients Neurology 58 2002 (178601790)
38. K.P. Wandinger, C.S. Sturzebecher, B. Bielekova, G. Detore, A. Rosenwald, L.M. Staudt, H.F. McFarland, and R. Martin Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes Ann. Neurol. 50 2001 349 357
39. G.J. Williams, and P.L. Witt Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex J. Interferon Cytokine Res. 18 1998 967 975